BIOMODEX Launches Synthetic Clot Product for Neurovascular Training
19 Oct 2021
BIOMODEX® is a Boston and Paris-based medical technology company whose mission is to transform the way physicians train and rehearse procedures
BIOMODEX Launches Synthetic Clot Product. (Credit: Arek Socha from Pixabay.)
BIOMODEX®, the leader in biorealistic haptic simulators for physician training and rehearsals, has announced the launch of Thrombotech™, a new hydrogel-based synthetic clot product that can be used for neurovascular training using EVIAS Plus™ – Biomodex’s innovative training solution for the treatment of ischemic stroke.
Thrombotech mimics the density and texture of an actual human blood clot. It can be inserted into a Biomodex 3D printed blood vessel cartridge that plugs into the EVIAS Plus station. Physicians can then practice retrieving the clot using aspiration and mechanical thrombectomy techniques. A Distal Clot Filter allows physicians to see if they effectively retrieved the clot. This technology stands to benefit medical device companies that are developing new devices for thrombectomies and for fellows who are training for these complex emergency procedures.
“Medtech companies and physicians are excited by Thrombotech because of its realistic nature,” said Ziad Rouag, President and CEO of Biomodex. “Clients using our biorealistc haptic simulators were telling stories about buying children’s slime or using chicken livers to simulate clots, none of which were realistic for training and rehearsals. So we set out to develop our own solution.”
Thrombotech is available in three densities: Soft, Medium, and Hard. Soft mimics Red Blood Cell (RBC) rich clots, Medium mimics an RBC/Fibrin clot, and Hard mimics a Fibrin-rich clot. The solution is also fully customizable; the density can be adjusted, or ingredients can be added to mimic calcium buildup.
“The realism of Thrombotech is unmatched by anything on the market today. Having a clot solution that accurately represents the density and texture of a human clot will better serve those training for complex thrombectomy procedures. This could help speed the advancement of new medical devices and training on those devices, bringing cutting edge treatments to patients faster,” said Keith Lauver, Chief Marketing Officer of Biomodex.
Source: Company Press Release
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.